Bio-Rad and Bruker Sign Joint Product Development and Co-Marketing Agreement

  Bio-Rad Laboratories, Inc.
(NYSE: BIO) and (NYSE: BIOb), a multinational manufacturer and distributor
of life science research and clinical diagnostic products, and Bruker
Corporation (NASDAQ: BRKR), a leading manufacturer of mass spectrometry
(MS) instruments, today announced that they have signed an exclusive
partnership agreement to develop and market new products based on Bio-Rad's
surface-enhanced laser desorption/ionization (SELDI) technology in
combination with Bruker's matrix-assisted laser desorption/ionization
time-of-flight (MALDI-TOF/TOF) mass spectrometers for applications of
high-throughput protein profiling and identification. The products will
provide new solutions for biomarker discovery, in particular, the detection
and high-confidence identification of intact peptides and proteins under 30
kilodaltons, which are known to be challenging for currently available
technologies to identify.

"We're confident that Bio-Rad's SELDI technology combined with the flexibility delivered by Bruker's TOF/TOF systems will offer tangible benefits to researchers for protein biomarker discovery," said Brad Crutchfield, Bio-Rad Vice President and Life Science Group Manager. "We welcome the opportunity to work with Bruker, a company that, similar to Bio-Rad, has a long history of advancing life science research through its commitment to customer support."

"We are excited about working with Bio-Rad," said Dr. Gary Kruppa, Vice President for Business Development at Bruker Daltonics. "Bruker Daltonics' high-performance TOF/TOF technology will bring a new dimension to protein profiling and identification, expanding the capabilities of Bio-Rad's established SELDI technology. New products based on this combination of technologies will allow access to new technical capabilities and new market segments in applied proteomics, enabling researchers to better identify and characterize new biomarkers."

About Bio-Rad

Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIOb), has remained at the center of scientific discovery for more than 50 years, manufacturing and distributing a broad range of products for the life science research and clinical diagnostic markets. Bio-Rad is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 85,000 research and industry customers worldwide through its global network of operations. The company employs over 6,500 people globally and had revenues exceeding $1.7 billion in 2008. For more information, visit www.bio-rad.com.

About Bruker Daltonics

Bruker Daltonics is a leading manufacturer of mass spectrometry (MS) instruments and accessories for life science, pharmaceutical, biochemical and chemical research as well as for applied analytical tasks in forensics and food safety. Technical solutions are based on a comprehensive range of MALDI-TOF/TOF, ESI-Qq-TOF, ESI-ITMS, and ESI/MALDI-FTMS mass spectrometry systems, as well as automated sample handling systems and productivity enhancing software. For more information about Bruker Daltonics and Bruker Corporation (NASDAQ: BRKR), please visit www.bdal.com and www.bruker.com.

This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, "believe," "expect," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company's risks and uncertainties, please refer to the "Risk Factors" in the Company's public reports filed with the Securities and Exchange Commission, including the Company's most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc., disclaims any obligation to update these forward-looking statements.

For more information, contact: Bio-Rad Laboratories, Inc. Tina Cuccia Corporate Communications Manager 510-724-7000 Email Contact Bruker Corporation Stacey Desrochers Investor Relations 978-663-3660 x 1115 Email Contact